Shkreli is accused of defrauding investors in his now-defunct healthcare-focused hedge fund MSMB Capital. He's also accused of misappropriating assets from Retrophin, a publicly traded biotech company he founded and once led, as his "personal piggy bank" to pay off debts he incurred from a series of bad trades he made with his fund.
He has pleaded not guilty to the charges.
Shkreli is the founder of Turing Pharmaceuticals, a biotech startup. He became infamous this year when his company acquired the rights to Daraprim, an antiparasitic drug used to treat toxoplasmosis, and immediately hiked the price from $13.50 to $750 per pill.
MOMENTS AGO: Martin Shkreli leaves court in large media scrum, makes no comment about his case.https://t.co/V1quu2usTh